Cargando…

Effects of insulin on human pancreatic cancer progression modeled in vitro

BACKGROUND: Pancreatic adenocarcinoma is one of the most lethal cancers, yet it remains understudied and poorly understood. Hyperinsulinemia has been reported to be a risk factor of pancreatic cancer, and the rapid rise of hyperinsulinemia associated with obesity and type 2 diabetes foreshadows a ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Michelle T, Lim, Gareth E, Skovsø, Søs, Yang, Yu Hsuan Carol, Albrecht, Tobias, Alejandro, Emilyn U, Hoesli, Corinne A, Piret, James M, Warnock, Garth L, Johnson, James D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233074/
https://www.ncbi.nlm.nih.gov/pubmed/25373319
http://dx.doi.org/10.1186/1471-2407-14-814
_version_ 1782344683553292288
author Chan, Michelle T
Lim, Gareth E
Skovsø, Søs
Yang, Yu Hsuan Carol
Albrecht, Tobias
Alejandro, Emilyn U
Hoesli, Corinne A
Piret, James M
Warnock, Garth L
Johnson, James D
author_facet Chan, Michelle T
Lim, Gareth E
Skovsø, Søs
Yang, Yu Hsuan Carol
Albrecht, Tobias
Alejandro, Emilyn U
Hoesli, Corinne A
Piret, James M
Warnock, Garth L
Johnson, James D
author_sort Chan, Michelle T
collection PubMed
description BACKGROUND: Pancreatic adenocarcinoma is one of the most lethal cancers, yet it remains understudied and poorly understood. Hyperinsulinemia has been reported to be a risk factor of pancreatic cancer, and the rapid rise of hyperinsulinemia associated with obesity and type 2 diabetes foreshadows a rise in cancer incidence. However, the actions of insulin at the various stages of pancreatic cancer progression remain poorly defined. METHODS: Here, we examined the effects of a range of insulin doses on signalling, proliferation and survival in three human cell models meant to represent three stages in pancreatic cancer progression: primary pancreatic duct cells, the HPDE immortalized pancreatic ductal cell line, and the PANC1 metastatic pancreatic cancer cell line. Cells were treated with a range of insulin doses, and their proliferation/viability were tracked via live cell imaging and XTT assays. Signal transduction was assessed through the AKT and ERK signalling pathways via immunoblotting. Inhibitors of AKT and ERK signalling were used to determine the relative contribution of these pathways to the survival of each cell model. RESULTS: While all three cell types responded to insulin, as indicated by phosphorylation of AKT and ERK, we found that there were stark differences in insulin-dependent proliferation, cell viability and cell survival among the cell types. High concentrations of insulin increased PANC1 and HPDE cell number, but did not alter primary duct cell proliferation in vitro. Cell survival was enhanced by insulin in both primary duct cells and HPDE cells. Moreover, we found that primary cells were more dependent on AKT signalling, while HPDE cells and PANC1 cells were more dependent on RAF/ERK signalling. CONCLUSIONS: Our data suggest that excessive insulin signalling may contribute to proliferation and survival in human immortalized pancreatic ductal cells and metastatic pancreatic cancer cells, but not in normal adult human pancreatic ductal cells. These data suggest that signalling pathways involved in cell survival may be rewired during pancreatic cancer progression.
format Online
Article
Text
id pubmed-4233074
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42330742014-11-17 Effects of insulin on human pancreatic cancer progression modeled in vitro Chan, Michelle T Lim, Gareth E Skovsø, Søs Yang, Yu Hsuan Carol Albrecht, Tobias Alejandro, Emilyn U Hoesli, Corinne A Piret, James M Warnock, Garth L Johnson, James D BMC Cancer Research Article BACKGROUND: Pancreatic adenocarcinoma is one of the most lethal cancers, yet it remains understudied and poorly understood. Hyperinsulinemia has been reported to be a risk factor of pancreatic cancer, and the rapid rise of hyperinsulinemia associated with obesity and type 2 diabetes foreshadows a rise in cancer incidence. However, the actions of insulin at the various stages of pancreatic cancer progression remain poorly defined. METHODS: Here, we examined the effects of a range of insulin doses on signalling, proliferation and survival in three human cell models meant to represent three stages in pancreatic cancer progression: primary pancreatic duct cells, the HPDE immortalized pancreatic ductal cell line, and the PANC1 metastatic pancreatic cancer cell line. Cells were treated with a range of insulin doses, and their proliferation/viability were tracked via live cell imaging and XTT assays. Signal transduction was assessed through the AKT and ERK signalling pathways via immunoblotting. Inhibitors of AKT and ERK signalling were used to determine the relative contribution of these pathways to the survival of each cell model. RESULTS: While all three cell types responded to insulin, as indicated by phosphorylation of AKT and ERK, we found that there were stark differences in insulin-dependent proliferation, cell viability and cell survival among the cell types. High concentrations of insulin increased PANC1 and HPDE cell number, but did not alter primary duct cell proliferation in vitro. Cell survival was enhanced by insulin in both primary duct cells and HPDE cells. Moreover, we found that primary cells were more dependent on AKT signalling, while HPDE cells and PANC1 cells were more dependent on RAF/ERK signalling. CONCLUSIONS: Our data suggest that excessive insulin signalling may contribute to proliferation and survival in human immortalized pancreatic ductal cells and metastatic pancreatic cancer cells, but not in normal adult human pancreatic ductal cells. These data suggest that signalling pathways involved in cell survival may be rewired during pancreatic cancer progression. BioMed Central 2014-11-06 /pmc/articles/PMC4233074/ /pubmed/25373319 http://dx.doi.org/10.1186/1471-2407-14-814 Text en © Chan et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chan, Michelle T
Lim, Gareth E
Skovsø, Søs
Yang, Yu Hsuan Carol
Albrecht, Tobias
Alejandro, Emilyn U
Hoesli, Corinne A
Piret, James M
Warnock, Garth L
Johnson, James D
Effects of insulin on human pancreatic cancer progression modeled in vitro
title Effects of insulin on human pancreatic cancer progression modeled in vitro
title_full Effects of insulin on human pancreatic cancer progression modeled in vitro
title_fullStr Effects of insulin on human pancreatic cancer progression modeled in vitro
title_full_unstemmed Effects of insulin on human pancreatic cancer progression modeled in vitro
title_short Effects of insulin on human pancreatic cancer progression modeled in vitro
title_sort effects of insulin on human pancreatic cancer progression modeled in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233074/
https://www.ncbi.nlm.nih.gov/pubmed/25373319
http://dx.doi.org/10.1186/1471-2407-14-814
work_keys_str_mv AT chanmichellet effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT limgarethe effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT skovsøsøs effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT yangyuhsuancarol effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT albrechttobias effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT alejandroemilynu effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT hoeslicorinnea effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT piretjamesm effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT warnockgarthl effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro
AT johnsonjamesd effectsofinsulinonhumanpancreaticcancerprogressionmodeledinvitro